Anaplastic gliomas are malignant neoplasms of the brain that remain frustratingly difficult to treat. The mean survival for the most malignant of these tumors-glioblastoma multiforme-is less than one year, and even the less aggressive members of this group of brain tumors generally kill their victims within 2-4 years. This state of affairs is due to the fact that anaplastic gliomas are relatively resistant to the effects of conventional radiation and chemotherapy-agents which inhibit a limited number of cellular targets. This in turn argues that other components of the glioma cell machinery which contribute to the malignant phenotype need to be identified and studied, in the hope of eventually developing methods that could inhibit their function and thus block this malignant behavior. It is the underlying hypothesis of this proposal that molecular motors, a class of enzymes that produce movement at the expense of ATP hydrolysis, represent such a component. These motors, whose importance in oncology has been underappreciated, are particularly important components in three elements of the malignant repertoire of gliomas-their ability to invade normal brain, their ability to generate a blood supply, and their ability to proliferate in an uncontrollable manner. Data will be presented which establishes that inhibiting one of these motors-myosin II-with non-toxic drugs blocks invasiveness, and that studying the molecular physiology of this motor protein yields new insights into how it works and is regulated. In this project, I will propose to: 1) study in greater detail the specific role(s) that myosin II plays in glioma invasion, and 2) examine the molecular basis for the regulation of myosin II activity. Methods will be developed that will test the feasibility of molecular genetic approaches to blocking the activity of myosin II in situ in glioma and endothelial cells. Data will also be presented to suggest that these approaches may also ultimately be applied to other molecular motors, such as the kinesins, that power the mitotic apparatus.

Project Start
1998-02-01
Project End
1999-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Rosenfeld, Steven S; Xing, Jun; Chen, Li-Qiong et al. (2003) Myosin IIb is unconventionally conventional. J Biol Chem 278:27449-55
Choi, Chulhee; Gillespie, G Yancey; Van Wagoner, Nicholas J et al. (2002) Fas engagement increases expression of interleukin-6 in human glioma cells. J Neurooncol 56:13-9
Rosenfeld, S S; Jefferson, G M; King, P H (2001) ATP reorients the neck linker of kinesin in two sequential steps. J Biol Chem 276:40167-74
Oh, J W; Drabik, K; Kutsch, O et al. (2001) CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 166:2695-704
Han, X; Stewart Jr, J E; Bellis, S L et al. (2001) TGF-beta1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate. Oncogene 20:7976-86
Dong, Y; Benveniste, E N (2001) Immune function of astrocytes. Glia 36:180-90
Ma, Z; Qin, H; Benveniste, E N (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol 167:5150-9
Lee, S J; Drabik, K; Benveniste, E N (2001) Cloning of rat calcium-modulating cyclophilin ligand. DNA Seq 12:209-13
Xing, J; Wriggers, W; Jefferson, G M et al. (2000) Kinesin has three nucleotide-dependent conformations. Implications for strain-dependent release. J Biol Chem 275:35413-23
Gladson, C L; Stewart, J E; Olman, M A et al. (2000) Attachment of primary neonatal rat astrocytes to vitronectin is mediated by integrins alphavbeta5 and alpha8beta1: modulation by the type 1 plasminogen activator inhibitor. Neurosci Lett 283:157-61

Showing the most recent 10 out of 20 publications